Drugs / JNJ-64232025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03550950 | Jun 2018 → Feb 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64232025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03550950 ↗ |
| Route | Intravenous | “JNJ-64232025 will be administered as IV infusion.” NCT03550950 ↗ |